Literature DB >> 9591925

Effect of prostaglandin E1 on pulmonary hypertension after protamine injection during cardiac surgery.

K Abe1, T Sakakibara, Y Miyamoto, K Ohnishi.   

Abstract

BACKGROUND: The effects of prostaglandin E1 on pulmonary hypertension were assessed after protamine injection at the end of cardiopulmonary bypass during cardiac surgery.
METHODS: Ten patients scheduled for cardiac surgery presented with pulmonary hypertension (mean pulmonary artery pressure greater than 30 mmHg) after protamine injection and were treated by infusion of 0.02 microg x kg(-1) x min(-1) prostaglandin E1. Hemodynamic measurements were made on occasions after cardiopulmonary bypass. Prostaglandin E1 decreased pulmonary artery pressure, pulmonary vascular resistance, right ventricular stroke work index and pulmonary vascular resistance/systemic vascular resistance ratio, but did not change blood pressure, systemic vascular resistance, left ventricular stroke work index or cardiac output.
CONCLUSION: Prostaglandin E1 normalized pulmonary hypertension after protamine injection, but did not change arterial blood pressure and cardiac output.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9591925     DOI: 10.1007/s002280050414

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  2 in total

1.  Fatal right ventricular failure and pulmonary hypertension after protamine administration during cardiac transplantation.

Authors:  Bibek S Pannu; Devang K Sanghavi; Pramod K Guru; Dereddi Raja Reddy; Vivek N Iyer
Journal:  Indian J Crit Care Med       Date:  2016-03

2.  Perioperative management with phosphodiesterase type 5 inhibitor and prostaglandin E1 for moderate portopulmonary hypertension following adult-to-adult living-donor liver transplantation: a case report.

Authors:  Takashi Onoe; Asuka Tanaka; Kohei Ishiyama; Kentaro Ide; Hirotaka Tashiro; Hideki Ohdan
Journal:  Surg Case Rep       Date:  2018-02-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.